- Home
- CBFV vs BDTX Comparison
CBFV vs BDTX Comparison
Compare CBFV & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CBFV | BDTX |
|---|---|---|
| Founded | 1901 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 193.1M | 171.9M |
| IPO Year | 2014 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CBFV | BDTX |
|---|---|---|
| Price | $36.56 | $1.89 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $38.00 | $9.67 |
| AVG Volume (30 Days) | 7.0K | ★ 2.2M |
| Earning Date | 04-22-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.12% | N/A |
| EPS Growth | N/A | ★ 130.71 |
| EPS | ★ 0.73 | N/A |
| Revenue | ★ $43,557,000.00 | N/A |
| Revenue This Year | $48.93 | N/A |
| Revenue Next Year | $7.97 | N/A |
| P/E Ratio | $49.88 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $27.49 | $1.60 |
| 52 Week High | $38.86 | $4.94 |
Technical Indicators
Market Signals| Indicator | CBFV | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 47.72 | 46.84 |
| Support Level | $34.06 | $1.60 |
| Resistance Level | $37.60 | $2.30 |
| Average True Range (ATR) | 0.79 | 0.16 |
| MACD | -0.17 | 0.05 |
| Stochastic Oscillator | 33.57 | 47.97 |
Price Performance
Historical ComparisonAbout CBFV CB Financial Services Inc.
CB Financial Services Incis a bank holding company headquartered in Carmichaels, Pennsylvania. The company had one reportable segment, community banking services. The Bank also has a loan production office in Allegheny County, a loan production office and a corporate center in Washington County, and an operations center in Greene County, Pennsylvania. The Bank is a community-oriented institution offering residential and commercial real estate loans, commercial and industrial loans, and consumer loans, as well as a variety of deposit products for individuals and businesses in its market area.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.